سعر ليفونانديكس 0.03مجم 35 قرص 2026

Levonorgestrel 0.03 mg (30 micrograms) film-coated tablets, pack of 35 (progestogen-only oral contraceptive).

• Oral contraception.Population: Women of reproductive ageelectronic medicines compendium (eMC) / MHRA

• Very common (>=10%): changes in vaginal bleeding pattern, including spotting, menorrhagia/metrorrhagia and amenorrhoea.International label, equivalent formulation · electronic medicines compendium (eMC) / MHRA
• Also reported: headache, migraine, dizziness, nausea, vomiting, depressed mood, weight change, decreased or increased libido, allergic reactions.International label, equivalent formulation · electronic medicines compendium (eMC) / MHRA

• Known or suspected pregnancy.International label, equivalent formulation · electronic medicines compendium (eMC) / MHRA
• Presence or history of severe hepatic disease while liver function values have not returned to normal; presence or history of liver tumours.International label, equivalent formulation · electronic medicines compendium (eMC) / MHRA
• History of or existing thromboembolic processes (e.g. stroke, myocardial infarction).International label, equivalent formulation · electronic medicines compendium (eMC) / MHRA

• Does not protect against HIV infection or other sexually transmitted diseases.International label, equivalent formulation · electronic medicines compendium (eMC) / MHRA
• Stop immediately on first occurrence or worsening of migrainous or unusually severe headaches, sudden visual or hearing disturbances, signs of thrombophlebitis or thromboembolism, jaundice or hepatitis, or pregnancy; stop 6 weeks before elective major surgery or prolonged immobilisation.International label, equivalent formulation · electronic medicines compendium (eMC) / MHRA
• Slightly increased relative risk of breast cancer diagnosis in current oral contraceptive users (evidence for causation with progestogen-only pills less conclusive); in women with hypertension the risk of stroke may be slightly enhanced.International label, equivalent formulation · electronic medicines compendium (eMC) / MHRA

• Hepatic enzyme inducers (phenytoin, barbiturates, primidone, carbamazepine, rifampicin; possibly oxcarbazepine, topiramate, felbamate, griseofulvin, St John's wort)May reduce contraceptive efficacy; use a barrier method during short-term treatment and for 28 days after stopping; with long-term enzyme inducers use another reliable non-hormonal method.electronic medicines compendium (eMC) / MHRA
• HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitorsMay increase or decrease progestin plasma concentrations; consult the HIV/HCV medicine information and consider an additional barrier method.electronic medicines compendium (eMC) / MHRA

• Contraindicated during pregnancy; withdraw immediately if pregnancy occurs. Epidemiological studies have shown neither an increased risk of birth defects after prior use nor a teratogenic effect with inadvertent use in early pregnancy.International label, equivalent formulation · electronic medicines compendium (eMC) / MHRA
• Progestogen-only pills can be used by breastfeeding women; no evidence of a detrimental effect on breast milk or infant growth and development; can be started up to 21 days post-partum.International label, equivalent formulation · electronic medicines compendium (eMC) / MHRA

• Levonorgestrel: Delays or inhibits ovulation; may also affect cervical mucus and endometrium.